On Global ALS/MND Awareness Day, the story of Cai Lei – a former Chinese e-commerce executive turned advocate – highlights resilience in the face of one of medicine’s most daunting challenges. Diagnosed with amyotrophic lateral sclerosis (ALS) in 2019, Cai has transformed his personal struggle into a mission to accelerate research and support for patients across Asia.
ALS, a progressive neurodegenerative disease with no known cure, affects over 200,000 people globally. Cai’s journey began when he noticed muscle weakness during routine workouts. Within months, the 42-year-old father could no longer lift his child. 'Time became my fiercest opponent,' he told KhabarAsia. 'But I realized my privilege could become others’ hope.'
In 2021, Cai founded the China ALS Research Foundation, channeling $14 million of his personal wealth into clinical trials and patient care programs. The initiative has since partnered with hospitals in Beijing and Shanghai to establish Asia’s first ALS-specific rehabilitation centers. Researchers credit Cai’s advocacy with doubling China’s ALS research funding since 2022.
This year’s awareness campaign focuses on early diagnosis, a critical factor in managing ALS progression. Medical experts emphasize that while Asia accounts for 40% of global cases, regional diagnostic delays average 12 months. 'Cai’s transparency about his symptoms has educated millions,' said Dr. Li Wen of Peking Union Medical College.
For investors and policymakers, the story underscores Asia’s growing role in biotech innovation. The Chinese mainland’s neurology therapeutics market is projected to reach $3.8 billion by 2026, driven by increased healthcare spending.
As sunset paints the Beijing skyline, Cai continues his daily physical therapy sessions while overseeing clinical trial updates. 'Every small breakthrough,' he says, 'is a step toward someone’s tomorrow.'
